Nick Johnson has joined CSS as director of business development for the US East Coast. Johnson has many years of experience in project management and business development, including spells at Cambrex, ChiRex and Archemis.
Lorantis Holdings has appointed Raj Parekh as its executive chairman. A founder and cso of Oxford GlycoSciences, Parekh is currently an 'entrepreneur in residence' at Abingworth, founding investors of Lorantis. He is also chairman of UK biotech company Chroma Therapeutics, and of biotechnology company Galapagos.
With Dennis Bourton retiring from Flexicon (Europe), responsibility for the company's European representatives passes to David Williams. He keeps the position of applications engineer, and will assist general sales manager Alan Walton in building European market share in conveyors, and bulk solids handling systems.
Dr Terry Hart has joined the board of directors at Peakdale Molecular as medicinal chemistry services director. He joins Peakdale from the Novartis Institute for Biomedical Research where he was unit head of discovery chemistry.
Cyprotex has appointed Dr Darwin Cheney as cso with immediate effect. He will be responsible for all laboratory operations. Dr David Leahy, who held the position previously, has become chief technical officer, with responsibility for new products and services.
RiverVest Venture Partners, a venture capital firm, has named Dr Dennis Wahr as its new managing director. A specialist in cardiac medicine, he has more than 25 years' experience in clinical practice and medical device entrepreneurship, is a former practicing interventional cardiologist and founder of Velocimed.
Dr David Mazzohas has joined nanotechnology company pSivida as a non-executive director. As president and ceo of Chugai Pharma USA, he has significant business development experience.
Dr Edward Tabor has joined Quintiles Transnational Corp. as executive director, regulatory & technical services. He joins Quintiles from the FDA, where he served as associate director for medical affairs in the Office of Blood Research and Review, in the Center for Biologics Evaluation and Research (CBER). At Quintiles, Dr. Tabor leads the regulatory consulting group for North America, providing strategic regulatory advice.